Synthetic Biology Market, By Product (Oligonucleotides , Enzymes , Synthetic Cells , Chassis Organism , and Others), By Technology (Genome Engineering , PCR Technology , Bioprocessing Technology , NGS Technology , Bioinformatics , Nanotechnology , and Others), By End User (Pharmaceutical Companies , Biotechnology Companies , CMO & CRO , and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI112

Pages :175

Formats :

Excel and PDF

Industry : Biotechnology

Synthetic Biology Market Size and Trends

The synthetic biology market is estimated to be valued at USD 21.90 Bn in 2025 and is expected to reach USD 90.73 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.5% from 2025 to 2032.

Synthetic Biology Market Key Factors

To learn more about this report, Request sample copy

The synthetic biology market is expected to witness significant growth over the forecast period. Advancements in DNA sequencing and gene-editing technologies are expanding the applications of synthetic biology in various healthcare verticals. Continuous research activities in synthetic DNA/RNA development for drug discovery and genome engineering is positively impacting the market growth. Adoption of synthetic approaches to design advanced biomaterials, medical devices, and biomolecules is gaining traction. Furthermore, rising R&D investments by biopharmaceutical companies and academic research institutions in the synthetic biology domain will propel the synthetic biology market during the projected timeframe.

Strategic investment by key players

Changes in public awareness of synthetic biology lead to an increase in the demand for synthetic biology products. Thus, key players in the market are engaged in investing in strategic development such as acquisition, collaboration, etc. in order to expand their business and address the demand. For instance, in November 2020, Codexis, Inc., a leading synthetic biology company in collaboration with a leading life science investor, Casdin Capital, announced the launch of SynBio Innovation Accelerator. Sumitomo Chemical is one of the leading players in Japan, and it launched SynBio Hub, a new organization in the U.S. to accelerate next-generation business utilizing synthetic biology.